Pembrolizumab in advanced renal cell carcinoma

Update Il y a 4 ans
Reference: EUCTR2016-000589-47

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

1. To estimate the objective response rate (ORR) per RECIST 1.1 as assessed by BICR in subjects with clear cell RCC. 2. To estimate the ORR per RECIST 1.1 as assessed by BICR in subjects with non-clear cell RCC.


Inclusion criteria

  • Renal cell carcinoma (clear cell & non-clear cell), or kidney cancer